XML 48 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
(LOSS) EARNINGS PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Schedule of calculation of earnings per share
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month and nine-month periods ended September 30, 2016 and 2015 were calculated as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2016
 
2015
 
2016
 
2015
(restated)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
$
(1,218.4
)
 
$
49.5

 
$
(1,894.4
)
 
$
94.2

 
 
 
 
 
 
 
 
Basic weighted-average number of common shares outstanding
349.5

 
344.9

 
346.5

 
340.8

Diluted effect of stock options, RSUs and other(a)
—

 
6.1

 
—

 
6.4

Diluted weighted-average number of common shares outstanding
349.5

 
351.0

 
346.5

 
347.2

 
 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
 
Basic
$
(3.49
)
 
$
0.14

 
$
(5.47
)
 
$
0.28

Diluted
$
(3.49
)
 
$
0.14

 
$
(5.47
)
 
$
0.27


____________________________________
(a)
In the three-month and nine-month periods ended September 30, 2016, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
 
Three Months Ended
September 30,
 
Nine Months
Ended
September 30,
 
 
2016
 
2016(1)
Basic weighted-average number of common shares outstanding
 
349.5

 
346.5

Diluted effect of stock options, RSUs and other
 
0.8

 
3.4

Diluted weighted-average number of common shares outstanding
 
350.3

 
349.9

____________________________________
(1)
The calculation of diluted weighted-average number of common shares outstanding for the nine-month period ended September 30, 2016 reflects the adjustment to the calculation for six-month period ended June 30, 2016 as a result of the adoption of a new accounting standard, effective as of January 1, 2016. Refer to Note 3 for further details.
Schedule of antidilutive securities excluded from earnings per share
The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
 
Three Months Ended
September 30,
 
Nine Months
Ended
September 30,
 
 
2016
 
2016(1)
Basic weighted-average number of common shares outstanding
 
349.5

 
346.5

Diluted effect of stock options, RSUs and other
 
0.8

 
3.4

Diluted weighted-average number of common shares outstanding
 
350.3

 
349.9

____________________________________
(1)
The calculation of diluted weighted-average number of common shares outstanding for the nine-month period ended September 30, 2016 reflects the adjustment to the calculation for six-month period ended June 30, 2016 as a result of the adoption of a new accounting standard, effective as of January 1, 2016. Refer to Note 3 for further details.